首页> 外文期刊>Journal of Medicinal Chemistry >Potent,Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine:Discovery of N-(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl-4-(2-oxo-2,3-dihydro-1H-imidazo4,5-bpyridin-1-yl
【24h】

Potent,Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine:Discovery of N-(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl-4-(2-oxo-2,3-dihydro-1H-imidazo4,5-bpyridin-1-yl

机译:口服生物可利用降钙素基因相关肽受体拮抗剂治疗偏头痛:N-(3R,6S)-6-(2,3-二氟苯基)-2-氧代-1-(2,2,2-三氟乙基)氮杂环庚烷-3-基-4-(2-氧代-2,3-二氢-1H-咪唑并4,5-b吡啶-1-基的发现

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Calcitonin gene-related peptide(CGRP)has been implicated in the pathogenesis of migraine.Herein we describe optimization of CGRP receptor antagonists based on an earlier lead structure containing a(3R)-amino-(6S)-phenylcaprolactam core.Replacement of the phenyl-imidazolinone with an azabenzimidazolone gave stable derivatives with lowered serum shifts.Extensive SAR studies of the C-6 aryl moiety revealed the potency-enhancing effect of the 2,3-difluorophenyl group,and trifluoroethylation of the N-1 amide position resulted in improved oral bioavailabilities,ultimately leading to clinical candidate 38(MK-0974).
机译:降钙素基因相关肽(CGRP)与偏头痛的发病机制有关。在此,我们描述了基于含有a(3R)-氨基-(6S)-苯基己内酰胺核心的早期先导结构的CGRP受体拮抗剂的优化。用氮杂苯并咪唑酮取代苯基咪唑啉酮可得到稳定的衍生物,血清偏移降低。对C-6芳基部分的广泛SAR研究揭示了2,3-二氟苯基的效力增强作用,N-1酰胺位置的三氟乙基化提高了口服生物利用度,最终导致了临床候选药物38(MK-0974)。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号